1. Diagnostic performance of a streamlined 18F-choline PET-CT protocol for the detection of prostate carcinoma recurrence in combination with appropriate-use criteria. Issue 7 (July 2018) Authors: Frood, R.; Baren, J.; McDermott, G.; Bottomley, D.; Patel, C.; Scarsbrook, A. Journal: Clinical radiology Issue: Volume 73:Issue 7(2018) Page Start: 632 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EP-1337: PSA Kinetics: HDR prostate brachytherapy boost in combination with external beam radiotherapy. (April 2016) Authors: Rodda, S.; Sun, F.; Henry, A.; Franks, K.; Bottomley, D. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EP-2261: A single centre experience of HDR brachytherapy as salvage treatment for relapsed prostate cancer. (April 2018) Authors: Dugdale, E.; Slevin, F.; Rodda, S.; Bottomley, D.; Carey, B.; Smith, J.; Hulson, O.; Adiotomre, E.; Mason, J.; Bownes, P.; Henry, A. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S1249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Intralesional tumour necrosis factor combined with interferon gamma in metastatic melanoma. Issue 6683 (13th May 1989) Authors: Retsas, S.; Leslie, M.; Bottomley, D. Journal: BMJ Issue: Volume 298:Issue 6683(1989) Page Start: 1290 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO-0734: Long term outcomes stratified by age for men treated with monotherapy I-125 permanent brachytherapy. (April 2015) Authors: Mason, M.; Rodda, S.L.; Musunuru, H.; Collier, N.; Al-Qaisieh, B.; Smith, J.; Bownes, P.; Franks, K.; Carey, B.; Bottomley, D.; Henry, A. Journal: Radiotherapy and oncology Issue: Volume 115(2015)Supplement 1 Page Start: S363 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PO-0977: Ten year patient reported Quality of Life following I-125 prostate brachytherapy monotherapy. (April 2016) Authors: Henry, A.; Sethugavalar, B.; Witteveen, T.; Al-Qaisieh, B.; Bownes, P.; Smith, J.; Carey, B.; Franks, K.; Mitchell, D.; Bottomley, D. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PO-1054 LDR versus HDR brachytherapy boost in prostate cancer patients - a retrospective analysis. (April 2019) Authors: Rodda, S.; Murray, L.; Bottomley, D.; Bownes, P.; Wilkinson, C.; Adiotomre, E.; Al-Qaisieh, B.; Dugdale, E.; Hulson, O.; Mason, J.; Smith, J.; Henry, A.M. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S587 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. Issue 9 (September 2018) Authors: Parikh, S.; Murray, L.; Kenning, L.; Bottomley, D.; Din, O.; Dixit, S.; Ferguson, C.; Handforth, C.; Joseph, L.; Mokhtar, D.; White, L.; Wright, G.; Henry, A.M. Journal: Clinical oncology Issue: Volume 30:Issue 9(2018) Page Start: 548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy. Issue 7 (July 2015) Authors: Henry, A.M.; Rodda, S.L.; Mason, M.; Musunuru, H.; Al-Qaisieh, B.; Bownes, P.; Smith, J.; Franks, K.; Carey, B.; Bottomley, D. Journal: Clinical oncology Issue: Volume 27:Issue 7(2015) Page Start: 382 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The National Radium-223 Dichloride Audit Group: Data from Patients in 17 UK Oncology Centres with Metastatic Castrate-resistant Prostate Cancer Treated with Radium-223 Dichloride. Issue 2 (February 2019) Authors: Randhawa, M.; Jones, R.; Stratton, I.; Bahl, A.; Bottomley, D.; Carruthers, H. Journal: Clinical oncology Issue: Volume 31:Issue 2(2019) Page Start: e24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗